Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|16|7|777-787

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.16, Iss.7, 2016-03, pp. : 777-787

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pemetrexed/cisplatin worth it in malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1627, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Current chemotherapeutic treatment of malignant pleural mesothelioma

By Nowak Anna K   Byrne Michael J   Millward Michael J   Alvarez John M   Robinson Bruce WS  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2441-2449

Informa Healthcare

Access to resources Recommend Favorite

Malignant pleural mesothelioma: current treatments and emerging drugs

By Belli Carmen   Fennell Dean   Giovannini Monica   Gaudino Giovanni   Mutti Luciano  

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 3, 2009-09 ,pp. : 423-437

Informa Healthcare

Access to resources Recommend Favorite

Raltitrexed + cisplatin beneficial for malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Pemetrexed + cisplatin: first-line for malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1404, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite